A prospective view on disease course and associated biomarkers in Hereditary Cerebral Hemorrhage With Amyloidosis Dutch type (HCHWA-D) - HCHWA-D follow-up study

eids Universitair Medisch Centrum0 个研究点目标入组 150 人开始时间: 待定最近更新: 2024年4月15日

适应症

试验速览

暂无简介。

•1. Age >= 18y
•2. Presence of either the APP mutation or an (earlier occurrence of) ICH on
•CT/MRI suspect for CAA and a family history (first degree relative) of HCHWA-D.
•3. Ability and willingness to provide written informed consent
•Additional criteria for TRACK D-CAA subgroup:
•1. Age 25-60 (inclusive) years old
•2. Presence of APP mutation at position 693 (100% carrier) or one first-degree
•relative with the mutation (50% carrier in case participants do not want to
•know their mutation status)
•3. No symptomatic ICH or maximum of 1 symptomatic ICH > 1 year before study
•entry with ADL independence after the hemorrhage.

•1. Contra-indications for 3T/7T MRI as determined by the 7Tesla safety
•committee. (exclusion for a subpart of the study)
•2. Contraindications for lumbar puncture (exclusion for a subpart of the study)
•3. Contraindications for [18F]Florbetaben PET-CT (TRACK D-CAA subgroup only)

发起方